Skip to main content
V

VytalaHealth

VytalaHealth provides Seracal, a plant‑based, gluten‑free medical food powder that uses its proprietary Lym‑X‑Sorb® lipid technology to improve intestinal absorption of long‑chain fats, calories, and fat‑soluble nutrients. By enhancing nutrient bioavailability, the product helps patients with fat malabsorption disorders such as cystic fibrosis or pancreatic insufficiency achieve better weight gain and reduce gastrointestinal symptoms, and it is reimbursable under CMS as a medical food.

Malvern, United StatesFounded 202217700+ followers
Updated 2 months ago

Funding

$810K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

3ORH
Funding rounds are not available yet.

Founders

Product

Problem

Fat malabsorption prevents patients from efficiently absorbing dietary fats, calories, and fat‑soluble nutrients, leading to nutrient deficiencies, poor weight gain, and gastrointestinal symptoms. Traditional management often relies on restrictive diets, complex supplements, or costly medical interventions that may be ineffective or burdensome.

Solution

VytalaHealth offers Seracal, a clinically proven medical food powder designed to enhance the intestinal absorption of fats and essential micronutrients. The product leverages the proprietary lipid technology Lym‑X‑Sorb®, which utilizes natural digestion components such as lysophosphatidylcholine, monoglycerides, and fatty acids to capture and transport nutrients across the intestinal barrier. By increasing the bioavailability of long‑chain fats, choline, and essential fatty acids, Seracal helps reduce malabsorption‑related symptoms and supports healthier weight, height, and BMI outcomes. The powder is plant‑based, gluten‑free, taste‑neutral, and can be easily mixed into soft foods or snacks, providing a convenient alternative to tube feeding or parenteral nutrition. Seracal is eligible for reimbursement as a medical food under CMS, enabling broader patient access without expensive hospital visits.

Target Audience

Primary users are individuals with fat malabsorption disorders—including cystic fibrosis, pancreatic insufficiency, and other gastrointestinal conditions—and the healthcare providers (physicians, dietitians, and care teams) who prescribe nutritional support.

Features

  • Proprietary Lym‑X‑Sorb® lipid platform that captures and transports long‑chain fats and micronutrients across the gut epithelium
  • Clinically validated to improve fat, calorie, and fat‑soluble vitamin absorption in pediatric and adult patients with cystic fibrosis or pancreatic insufficiency
  • Plant‑based, gluten‑free, taste‑neutral powder that mixes readily into foods or snacks
  • Provides additional essential fatty acids and choline to support growth, weight gain, and overall health
  • Eligible for CMS reimbursement as a medical food, reducing out‑of‑pocket costs
  • Serves as a potential alternative to supplemental tube feeding or parenteral nutrition
This profile is AI-generated and may contain inaccuracies.